English
Afrikaans
Albanian
Arabic
Armenian
Azerbaijani
Basque
Belarusian
Bulgarian
Catalan
Chinese (Simplified)
Chinese (Traditional)
Croatian
Czech
Danish
Dutch
Estonian
Filipino
Finnish
French
Galician
Georgian
German
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Malay
Maltese
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese
Welsh
YiddishExpert of the Month Interviews
Gene Therapy in Hemophilia experts from around the world provide updates monthly on the latest information and news.
This Month's Video: Spark Phase 1/2 SPK-8011 Clinical Trial
Presented by: Stacy E. Croteau, MD, MMS Medical Director, Boston Hemophilia Center Assistant Professor of Pediatrics, Harvard Medical School Boston, Massachusetts
Additional Updates
Five Year Data Confirms Stable FIX Expression
Presented by: Wolfgang A. Miesbach, MD, PhD, Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main Germany.
What to Expect at the upcoming ISTH Congress in Gene Therapy Hemophilia
Presented by: David Lillicrap, MD, FRCPC, Department of Pathology & Molecular Medicine, Queen's University, Kingston, Ontario
Highlights from the ASGCT 24th Annual Meeting
Presented by: Wolfgang A. Miesbach, MD, PhD, Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main Germany.
Hepatoxicity and Gene Therapy
Presented by: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC, Los Angeles, California.
Durability: Factor VIII and Factor IX Differences
Presented by: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC, Los Angeles, California.
